UY38293A - Nuevos compuestos y composiciones de c-manósido antagonistas de fimh - Google Patents

Nuevos compuestos y composiciones de c-manósido antagonistas de fimh

Info

Publication number
UY38293A
UY38293A UY0001038293A UY38293A UY38293A UY 38293 A UY38293 A UY 38293A UY 0001038293 A UY0001038293 A UY 0001038293A UY 38293 A UY38293 A UY 38293A UY 38293 A UY38293 A UY 38293A
Authority
UY
Uruguay
Prior art keywords
compositions
compounds
new
manoside
fimh antagonists
Prior art date
Application number
UY0001038293A
Other languages
English (en)
Inventor
L Stewart Eugene
Joseph Bishop Michael
J Colandrea Vincent
Iulia Strambeanu
Walter Janetka James
Louisa Widdowson Katherine
Yuehu Li
Kathryn MCGRANE Laurel
Original Assignee
Glaxosmithkline Ip Dev Ltd
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Fimbrion Therapeutics Inc filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY38293A publication Critical patent/UY38293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente memoria nuevos compuestos y composiciones de C manósido y su aplicación como productos farmacéuticos para el tratamiento de enfermedades humanas. También se proporcionan métodos para inhibir la actividad de FimH en un sujeto humano con el fin de tratar enfermedades tales como la infección del tracto urinario.
UY0001038293A 2018-07-10 2019-07-08 Nuevos compuestos y composiciones de c-manósido antagonistas de fimh UY38293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695993P 2018-07-10 2018-07-10
US201862755588P 2018-11-05 2018-11-05

Publications (1)

Publication Number Publication Date
UY38293A true UY38293A (es) 2020-05-29

Family

ID=67957191

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038293A UY38293A (es) 2018-07-10 2019-07-08 Nuevos compuestos y composiciones de c-manósido antagonistas de fimh

Country Status (24)

Country Link
US (3) US11111262B2 (es)
EP (1) EP3820856B9 (es)
JP (2) JP7309862B2 (es)
KR (1) KR20210031682A (es)
CN (1) CN112334455B (es)
AU (1) AU2019301946B2 (es)
BR (1) BR112021000370A2 (es)
CA (1) CA3105940A1 (es)
CL (1) CL2021000033A1 (es)
DK (1) DK3820856T3 (es)
ES (1) ES2928634T3 (es)
HR (1) HRP20221381T1 (es)
HU (1) HUE060140T2 (es)
IL (1) IL279993B2 (es)
LT (1) LT3820856T (es)
MX (1) MX2021000340A (es)
PH (1) PH12020551905A1 (es)
PL (1) PL3820856T3 (es)
PT (1) PT3820856T (es)
RS (1) RS63712B1 (es)
SG (1) SG11202011066XA (es)
TW (1) TWI821328B (es)
UY (1) UY38293A (es)
WO (1) WO2020012336A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3820856T (lt) 2018-07-10 2022-11-10 Glaxosmithkline Intellectual Property Development Limited C-manozido junginiai, naudingi šlapimo takų infekcijoms gydyti
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
CN113461753B (zh) 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用
KR20230028268A (ko) 2020-05-29 2023-02-28 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 헤테로시클릭 화합물
AU2022377394A1 (en) 2021-11-01 2024-06-13 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
ATE271060T1 (de) 1993-11-18 2004-07-15 Univ Washington Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen
EP1192038B1 (en) 1999-06-28 2003-11-05 Lear Corporation Method of forming a blow-molded plastic part having a living hinge
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
ATE419880T1 (de) 2000-06-09 2009-01-15 Baylor College Medicine Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen
AU2003274127A1 (en) 2003-10-08 2005-04-21 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
EP3492483A1 (en) 2009-10-22 2019-06-05 The Washington University Compounds and methods for treating bacterial infections
AU2010333017B2 (en) 2009-12-14 2016-06-16 University Of Basel Mannose derivatives as antagonists of bacterial adhesion
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
WO2013134415A1 (en) 2012-03-07 2013-09-12 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP2690105A1 (en) 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
WO2014055474A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014100158A1 (en) 2012-12-18 2014-06-26 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
AU2014248717B2 (en) 2013-03-12 2018-03-29 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections
CA2994778C (en) 2015-08-05 2024-01-02 Enterome Mannose derivatives useful for treating pathologies associated with adherent e. coli
US20200002303A1 (en) 2016-03-11 2020-01-02 Fimbrion Therapeutics, Inc. C-glycoside compounds useful for treating disease
RU2018131440A (ru) 2016-03-23 2020-04-23 Фимбрион Терапеутикс, Инк. Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания
EP3697924A1 (en) 2017-10-16 2020-08-26 Enterome New tools for assessing fimh blockers therapeutic efficiency
LT3820856T (lt) 2018-07-10 2022-11-10 Glaxosmithkline Intellectual Property Development Limited C-manozido junginiai, naudingi šlapimo takų infekcijoms gydyti

Also Published As

Publication number Publication date
CL2021000033A1 (es) 2021-07-30
BR112021000370A2 (pt) 2021-04-06
TWI821328B (zh) 2023-11-11
JP2022191325A (ja) 2022-12-27
LT3820856T (lt) 2022-11-10
IL279993B1 (en) 2023-09-01
HRP20221381T1 (hr) 2023-01-06
ES2928634T3 (es) 2022-11-21
PL3820856T3 (pl) 2022-12-19
EP3820856A1 (en) 2021-05-19
IL279993A (en) 2021-03-01
AU2019301946B2 (en) 2022-03-31
MX2021000340A (es) 2021-03-25
PH12020551905A1 (en) 2021-06-21
RS63712B1 (sr) 2022-11-30
CA3105940A1 (en) 2020-01-16
AU2019301946A1 (en) 2020-11-26
US20210017212A1 (en) 2021-01-21
SG11202011066XA (en) 2021-01-28
CN112334455B (zh) 2022-07-01
WO2020012336A1 (en) 2020-01-16
DK3820856T3 (da) 2022-10-24
JP2022511594A (ja) 2022-02-01
PT3820856T (pt) 2022-10-17
US11697665B2 (en) 2023-07-11
TW202019893A (zh) 2020-06-01
JP7309862B2 (ja) 2023-07-18
JP7483820B2 (ja) 2024-05-15
HUE060140T2 (hu) 2023-02-28
KR20210031682A (ko) 2021-03-22
US20210395287A1 (en) 2021-12-23
EP3820856B9 (en) 2023-07-12
IL279993B2 (en) 2024-01-01
EP3820856B1 (en) 2022-08-31
US11111262B2 (en) 2021-09-07
CN112334455A (zh) 2021-02-05
US20230287028A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
UY38293A (es) Nuevos compuestos y composiciones de c-manósido antagonistas de fimh
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CO2021008224A2 (es) Inhibidores de kif18a
NI201800124A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
NZ726695A (en) Gls1 inhibitors for treating disease
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
CR20110438A (es) Icam 1 soluble como biomarcador para predicción de respuesta terapéutica
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
MA51278A (fr) Utilisation d'un extrait végétal en tant qu'agent actif dans le traitement de maladies dermatologiques
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
NI201200196A (es) Agentes terapéuticos 976
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
BR112021022281A2 (pt) Novos compostos

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201203